# Avacta Group sign collaboration and license agreement with AffyXell Therapeutics

- Link: https://www.directorstalkinterviews.com/avacta-group-sign-collaboration-and-license-agreement-with-affyxell-therapeutics/412804576
- Published: 2020-02-03T07:08:58+00:00
- Author: Amilia Stone

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc **([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of Affimer^(®) biotherapeutics and reagents, today announced that 
it has signed a collaboration and license agreement with AffyXell Therapeutics, 
the recently established joint venture with Daewoong Pharmaceutical , to develop
Affimer proteins to be used by AffyXell for the generation of new cell and gene 
therapies.

Avacta and AffyXell will now work together to develop Affimer proteins against a
range of targets which, when produced by mesenchymal stem cells (MSCs), are intended
to inhibit inflammatory and autoimmune pathways and improve the overall efficacy
of MSCs, creating a next generation of stem cell therapies.

The initial focus for AffyXell will be on inflammatory and autoimmune diseases. 
In the longer term, there is potential for AffyXell to address oncology uses for
these Affimer-enabled cell and gene therapies.

Under the terms of the collaboration and license agreement, Avacta’s research and
development costs associated with generation of the Affimer proteins will be funded
by AffyXell.  In addition, Avacta will retain the rights to commercialise the Affimer
proteins outside of the field of cell therapies.

> **Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: **
> “The potential for AffyXell’s new class of cell therapies, which can be applied
> to a wide range of inflammatory and autoimmune diseases, is enormous. We are therefore
> very excited by the opportunity to be part of this new venture and to demonstrate
> the power of Affimer proteins in the field of engineered cell therapies.  
> “Our objective is for these cell therapies to finally fully address diseases, 
> such as inflammatory bowel diseases and multiple sclerosis, as well as other autoimmune
> diseases, such as chronic obstructive pulmonary disease. The potential to make
> a difference in the quality of life for millions of patients continues to inspires
> us, as we know it does our colleagues at Daewoong as well.    
> “From a commercial perspective, the global stem cell market is expected to be 
> worth USD16bn* by 2025.  AffyXell has a unique opportunity to combine two world-
> class technologies, Avacta’s Affimer antibody mimetic platform and Daewoong’s 
> proprietary technology for generating “off-the-shelf” allogeneic MSC therapies
> to create the next generation of stem cell therapies. We believe that this has
> the potential to create substantial value for stakeholders in the near future.”

* [https://www.grandviewresearch.com/press-release/global-stem-cells-market](https://www.grandviewresearch.com/press-release/global-stem-cells-market)

> **Seng-ho Jeon, CEO of Daewoong Pharmaceutical, commented:**
> “We are very excited to contract this Collaboration and License Agreement followed
> by the successful establishment of an innovative joint venture, AffyXell. Daewoong
> and Avacta Group will make every effort to AffyXell’s growth and its development
> of distinguished and innovative cell and gene therapy treatment.
> “As announced at the J.P. Morgan Healthcare Conference this January, Daewoong 
> has been inspired to partner global biotechnology companies like Avacta to create
> the best and the most comprehensive technology in new drug development field. 
> Starting from our very first cell and gene therapy specialized joint company, 
> we reaffirm our belief that our contract can not only further establish AffyXell
> to thrive as an leader of cell and gene therapy, but also, allow us to enhance
> quality of lives to those who suffer from rare and intractable conditions.”

Share on: